

Application No. 09/211,715  
Reply to Advisory Action of July 2, 2003

September 10, 2003  
S&L File No. P26,835-D USA

Ac-pAph-Chg-Arg-Gla-Pro-NH<sub>2</sub>; ~~Ac-pAph-Chg-Arg-Cys (CH<sub>2</sub>-COOH)-Pro-NH<sub>2</sub>;~~  
Ac-Pal(4)Me-Chg-Arg-Leu-Pro-NH<sub>2</sub>; Ac- (iBu) Nal (2) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
Ac-Phe (p-CONH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
Ac-pAph-Chg-Arg-N [1(1,3-dicarboxy) propyl] Gly-Pro-NH<sub>2</sub>;  
Ac-pAph-Chg-Dap (CH=N(CH<sub>3</sub>)<sub>2</sub>) -Leu-Pro-NH<sub>2</sub>;  
(2-quinolinoyl) -Phe (NH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
Ac-pAph-Chg-Arg-N (carboxymethyl) Gly-Pro-NH<sub>2</sub>;  
Ac-pAph-Chg-Arg- (carboxyethyl) Gly-Pro-NH<sub>2</sub>; Ac-mAph-Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
Alloc-pAph-Chg-PalMe(3) -Pen (CH<sub>2</sub>COOH)-Pro-NH<sub>2</sub>;  
~~Ac-pAph-Chg-Arg-N [1(1,3-dicarboxy) propyl] Gly-Pro-NH<sub>2</sub>;~~  
Ac-pAph-Ile-Arg-Leu-Pro-NH<sub>2</sub>; Ac-Phe (pNH<sub>2</sub>) -Chg-Arg- (Me) Leu-Pro-NH<sub>2</sub>;  
Ac- (Chx-CH<sub>2</sub>) Tyr-Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
(3-pyridoyl) -Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
(3-pyridoyl) -Nal (2) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
Ac-Pal(4)Me-Chg-Pal(4)Me-Leu-Pro-NH<sub>2</sub>; ~~Alloc-pAph-Chg-Arg-Leu-Pro-NH<sub>2</sub>;~~  
(4-isoquinolinoyl) -Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
Ac-pAph-Cha-PalMe(3) - (Me) Leu-Pro-NH<sub>2</sub>;  
Ac-pAph-Chg-PalMe(3) -Leu-Pro-NH<sub>2</sub>;  
(2-naphthyl-CH<sub>2</sub>) Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
(5-pyrazinoyl) Nal (2) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
(Benzoyl) - Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
Ac- (2-methylpentanyl) -Tyr-Ile-Arg-Leu-Pro-NH<sub>2</sub>;  
(2-pyridonyl) Phe (pNH<sub>2</sub>) Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
~~(Benzoyl) -Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;~~  
Ac- (2-methylpentyl) Tyr-Ile-Arg-Leu-Pro-NH<sub>2</sub>;  
Ac- (iBu) Phe (pCN) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;

Application No. 09/211,715  
Reply to Advisory Action of July 2, 2003

September 10, 2003  
S&L File No. P26,835-D USA

Ac- (2-methylbutyl) Tyr-Ile-Arg-Leu-Pro-NH<sub>2</sub>;  
Ac-Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>; Ac-Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Hyp-NH<sub>2</sub>;  
Ac-Tyr-Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
(2-naphthylsulfonyl) -Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
(2-methylbenzyl) -Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
(2-benzofuroyl) -Phe(pNH<sub>2</sub>) -Chg-Dab (CH=N(CH<sub>3</sub>)<sub>2</sub>) -Leu-Pro-NH<sub>2</sub>;  
Ac- (cyclopentenyl-CH<sub>2</sub>) Tyr-Ile-Arg-Leu-Pro-NH<sub>2</sub>;  
Ac-Pal (4) Me-Chg-PalMe(3) -Leu-Pro-NH<sub>2</sub>;  
Ac- (iBu) -Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>; and  
Ac- (Chx-CH<sub>2</sub>) -Tyr-Ile-Arg-Leu-Pro-NH<sub>2</sub>.

6. Claim ~~9~~ (Previously presented): A compound selected from the group consisting of Ac-pAph-Chg-Arg-Leu-NH<sub>2</sub> and Ac-pAph-Chg-Arg-Leu.

7. Claim ~~10~~ (Previously presented): A compound selected from the group consisting of (2-benzofuroyl) -pAph-Chg-PalMe(3) -NH<sub>2</sub> and Ac- (iBu) Phe (pNH<sub>2</sub>) -Chg-Arg-NH<sub>2</sub>.

4. Claim ~~11~~ (Currently amended): A compound selected from the group consisting of Alloc-pAph-Chg-PalMe(3) -NH<sub>2</sub>;  
(2-quinolinoyl) -pAph-Chg-PalMe(3) -NH<sub>2</sub>;  
Ac-pAph-Chg-PalMe(3) -NH (1-methoxycarbonyl) -1-cyclohexyl;  
Ac-pAph-Chg-Arg-NH<sub>2</sub>; (2-pyridoyl) -pAph-Chg-PalMe(3) -NH<sub>2</sub>;  
CF<sub>3</sub>C(O) - (iBu) Phe (pNH<sub>2</sub>) -Chg-Arg-NH<sub>2</sub>;  
Ac-pAph-Chg-PalMe(3) -NH- (1-methoxycarbonyl) -1-cyclopentyl;  
Ac-pAph-Chg-PalMe(3) -NH- (4-methoxycarbonyl-cyclohexyl) methyl;

Application No. 09/211,715  
 Reply to Advisory Action of July 2, 2003

September 10, 2003  
 S&L File No. P26,835-D USA

Ac-pAph-Chg-PalMe(3) -NH- (3-thienyl-2-carboxylic acid methyl ester);  
~~Ac-pAph-Chg-Arg-NH<sub>2</sub>; CF<sub>3</sub>C(O) - (iBu) Tyr-Chg-Arg- OH COOH;~~  
~~Ac-pAph-Chg-PalMe(3) -NH- (4-methoxycarbonyl-cyclohexyl) methyl;~~  
 Ac-pAph-Chg-PalMe(3) -NH<sub>2</sub>; Ac-pAph-Chg-Pal(3) (CH<sub>2</sub>COOH) -NH<sub>2</sub>;  
 (2-quinolinecarboxy) -pAph-Chg-PalMe(3)-NH<sub>2</sub>;  
 Ac-pAph-Chg-PalMe(3) -NH- (4-carboxycyclohexyl) methyl; and  
 CF<sub>3</sub>C (O) (iBu) -Tyr-Ile-Arg-NH<sub>2</sub>.

Claims 12-19 (Canceled)

6. Claim ~~20~~ (Previously presented): A compound selected from the group consisting of Ac-D-pAph-Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
 Ac-D-pAph-Chg-Arg-Gla-Pro-NH<sub>2</sub>;  
 Ac-D-pAph-Chg-Arg-Cys (CH<sub>2</sub>-COOH) -Pro-NH<sub>2</sub>;  
 Ac-D-pAph-Chg-Arg-N (carboxymethyl) Gly-Pro-NH<sub>2</sub>;  
 Ac-D-pAph-Chg-Arg- (carboxyethyl) Gly-Pro-NH<sub>2</sub>;  
 Ac-D-pAph-Chg-Arg-N [1(1,3-dicarboxy) propyl] Gly-Pro-NH<sub>2</sub>;  
 Ac-D-pAph-Ile-Arg-Leu-Pro-NH<sub>2</sub>; Alloc-D-pAph-Chg-Arg-Leu-Pro-NH<sub>2</sub>;  
 Ac-D-pAph-Chg-PalMe(3) -Leu-Pro-NH<sub>2</sub>; and Ac-D-pAph-Chg-Arg-NH<sub>2</sub>.

7. Claim ~~21~~ (Previously presented): A compound  
 Ac-D-pAph-Chg-PalMe(3) -Leu-Pro-NH<sub>2</sub>.

8. Claim ~~22~~ (Previously presented): A compound  
 Ac-D-pAph-Chg-PalMe(3) -NH<sub>2</sub>.

SYNNESTVEDT & LECHNER LLP

Application No. 09/211,715  
Reply to Advisory Action of July 2, 2003

September 10, 2003  
S&L File No. P26,835-D USA

9 · Claim ~~23~~ (Original): A compound Ac-Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>.

Claim 24 (Canceled)

10 · Claim ~~25~~ (Previously presented): A method of specifically inhibiting the activity of Factor Xa, comprising contacting the factor Xa with the compound as in claims 7, 8, 9, 10, 11, 20, 21, 22, or 23.

Claim 26 (Canceled)